Nishanth Selvakumar

The groundbreaking gene editing technology CRISPR-Cas9 is examined in the article "Gene Editing and CRISPR Technology: Unlocking the Potential to Cure Genetic Diseases Amidst Implications and Controversies" in order to determine whether it has the ability to treat genetic disorders. With its ability to precisely alter DNA sequences within living things, CRISPR-Cas9 presents previously unimaginable prospects in biotechnology, agriculture, and medicine. The paper emphasises how CRISPR-Cas9 might be used to cure genetic disorders including cystic fibrosis, sickle cell disease, and Huntington's disease by fixing flawed DNA at its source. Additionally, it examines the idea of personalised medicine, in which medical interventions may be adjusted to a patient's particular genetic profile. But the technology also raises moral and societal questions. Questions regarding eugenics and equality are raised in relation to the potential for "designer babies" and non-medical gene editing. Risks of unexpected genetic modifications and off-target effects are among the safety concerns that call for cautious regulation and responsible use. Despite these obstacles, the paper stresses the necessity of open communication between scientists, decision-makers, and the general public in order to achieve a balance between scientific innovation and responsible implementation. CRISPR-Cas9 has the ability to change healthcare and solve urgent genetic problems for the benefit of mankind by mindfully handling the ethical challenges.